Extended Release Tacrolimus Dosage Form for Organ Transplant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current once-daily tacrolimus formulations, such as Advagraf, have shown lower efficacy and higher rejection rates in organ transplant patients due to lower and less frequent concentration peaks, indicating a need for an improved regimen with similar or better efficacy to twice-daily tacrolimus with fewer adverse events.
Innovation Solution
A once-daily extended release tacrolimus dosage form that provides low fluctuation and a significantly lower Cmax while maintaining or exceeding the area under the curve (AUC), primarily releasing in the colon and lower ileum, allowing for a higher initial daily dose without increased adverse events, and is administered within 24 to 48 hours post-transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a once-daily tacrolimus formulation is used, then dosing frequency is reduced and patient compliance is improved, but drug concentration peaks become lower and less frequent leading to reduced efficacy
Solution Approach 1:
The patent modifies the release kinetics parameters of tacrolimus by using an extended-release formulation that provides sustained drug release throughout the dosing interval. This maintains therapeutic drug concentrations more consistently compared to immediate-release formulations, achieving both once-daily dosing convenience and sustained efficacy through controlled parameter changes in drug release rate and duration
Solution Approach 2:
The extended-release formulation creates a dynamic drug release profile that adapts to maintain therapeutic levels. The formulation dynamically releases tacrolimus over time to prevent the sharp peaks and troughs associated with immediate-release formulations, ensuring continuous therapeutic effect throughout the 24-hour dosing interval
2Reliability
If an immediate release formulation is used, then drug concentration peaks are higher providing better efficacy, but adverse events increase due to high Cmax
Solution Approach 1:
The patent changes the pharmacokinetic parameters by using an extended-release formulation that reduces Cmax while maintaining or improving AUC. This parameter modification allows achieving therapeutic efficacy through sustained release rather than high peak concentrations, thereby reducing concentration-dependent adverse events while maintaining reliability
Solution Approach 2:
The patent converts the potential harm of high peak concentrations into a benefit by using extended-release technology. Instead of allowing high Cmax values that cause adverse events, the formulation spreads drug release over time, transforming the concentrated harmful effect into a beneficial sustained therapeutic effect that maintains efficacy while reducing toxicity
3Reliability
If a higher initial daily dose is administered, then immunosuppression is improved and rejection risk is reduced, but adverse events increase
Solution Approach 1:
The patent enables administration of higher initial daily doses by using an extended-release formulation that controls the rate of drug release. This parameter change in release kinetics allows delivering higher total daily doses while maintaining lower instantaneous concentrations, thereby improving immunosuppression efficacy without proportionally increasing concentration-dependent adverse events
Data Source
AI summary
The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.